ZELTIQ

ZELTIQ Aesthetics, Inc. was an American medical device company founded in 2007 and headquartered in Sunnyvale, California. The company specialized in non-invasive fat reduction and body contouring technologies using its proprietary cryolipolysis platform, branded as CoolSculpting. The CoolSculpting procedure involves cooling fat cells to a temperature that causes their natural elimination without damaging surrounding tissues, providing a non-surgical alternative to liposuction.

ZELTIQ grew rapidly due to the increasing demand for minimally invasive aesthetic treatments. Its technology received FDA approval in 2010 for the treatment of subcutaneous fat in various body areas, including the abdomen, thighs, flanks, and double chin. The company marketed its devices primarily to dermatologists, plastic surgeons, and other trained medical professionals.

In 2015, ZELTIQ was acquired by its larger competitor, Johnson & Johnson, in a deal valued at approximately $2.4 billion. Following the acquisition, ZELTIQ continued to operate under its brand and expanded its product portfolio and geographic reach.

In 2017, the company was rebranded as Allergan Aesthetics, a division of AbbVie following Allergan’s acquisition of the aesthetic business from Johnson & Johnson. The CoolSculpting technology became a leading non-invasive fat reduction procedure globally, contributing significantly to the aesthetic medicine market.

ZELTIQ's innovations have played a pivotal role in popularizing non-invasive cosmetic procedures, and its technology remains widely used in medical aesthetic practices around the world.